

<b>Elder Pharmaceuticals Ltd.</b>						
<b>UNAUDITED FINANCIAL RESULTS ( PROVISIONAL) FOR THE QUARTER ENDED 30TH SEPTEMBER, 2008</b>						
						(Rupees lacs)
Sr. No.	Particulars	Quarter ended 30.09.2008 (Unaudited)	Quarter ended 30.09.2007 (Unaudited)	Half year ended 30.09.2008 (Unaudited)	Half year ended 30.09.2007 (Unaudited)	Previous year ended 31.03.2008 (Audited)
1	Net sales / Income from operations	15108.34	13227.47	29775.36	25296.49	55119.62
2	Other Income	184.57	123.70	282.84	205.95	516.71
	<b>Total Income</b>	<b>15292.91</b>	<b>13351.17</b>	<b>30058.20</b>	<b>25502.44</b>	<b>55636.33</b>
3	Total Expenditure					
	a) Increase ( - ) / Decrease ( + ) in stock in trade	1552.80	-402.50	1653.13	1220.28	1266.64
	b) Consumption of Materials	2722.45	2496.08	5873.68	3949.42	8650.70
	c) Purchase of traded goods	3404.60	4447.24	7336.72	7472.23	16673.99
	d) Employees cost	2135.36	1754.53	4221.02	3493.73	7466.86
	e) Depreciation	327.64	306.27	651.33	588.61	1061.08
	f) Other Expenditure	2682.60	2367.22	5243.03	4283.86	10528.89
4	<b>Total Expenditure</b>	<b>12825.45</b>	<b>10968.84</b>	<b>24978.91</b>	<b>21008.13</b>	<b>45648.16</b>
5	Interest ( Net )	761.33	456.20	1418.95	859.97	2130.28
6	Exceptional items					
7	Profit from ordinary activities before tax	1706.13	1926.13	3660.34	3634.34	7857.89
8	Tax expenses (Refer note number 5 below)	200.00	200.00	400.00	400.00	993.31
9	Net profit from ordinary activities after tax	<b>1506.13</b>	<b>1726.13</b>	<b>3260.34</b>	<b>3234.34</b>	<b>6864.58</b>
10	Extraordinary items (Net of tax expenses Rs. )					
11	Net profit for the period	<b>1506.13</b>	<b>1726.13</b>	<b>3260.34</b>	<b>3234.34</b>	<b>6864.58</b>
12	Paid up equity share capital (Face value Rs.10/-)	1885.75	1864.96	3771.50	1864.96	1879.22
13	Reserves excluding revaluation reserves	-	-	-	-	36476.43
14	Earnings Per Share (Not annualised)					
	Basic	7.99	9.26	17.29	17.34	36.74
	Diluted	7.46	9.26	16.76	17.34	36.61
15	Public Shareholding:					
	Number of shares	11626068	11724921	11626068	11724921	11657095
	Percentage of shareholding	61.65	62.86	61.65	62.86	62.76
Notes:						
1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 21st October, 2008.						
2) The statutory Auditors have carried out a limited review of the unaudited (provisional) financial results for the quarter ended 30th September, 2008.						
3) The Company operate in Pharmaceutical segment only. Hence, pursuant to accounting standard AS-17 on segment reporting, segmental information is not required to be given.						
4) Investor complaints pending at the beginning of the quarter - Nil. Received during the quarter - 10. Pending at the end of the quarter - Nil						
5) Provision for Tax includes current tax, deferred tax and fringe benefit tax.						
Place: Mumbai						
Date: 21st October, 2008						